News – Page 975 – Endpoints News

G1 touts PhII cancer data, but shares tank on placebo results; Merck bags another approved indication for Keytruda

7 years ago

On the heels of China approval, FibroGen and AstraZeneca spotlight more positive PhIII data for roxadustat

7 years ago

Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal

7 years ago

Cash-poor Agenus finds itself a generous partner in Gilead, shares surge

7 years ago

Google’s GV enlists machine learning pro Rosana Kapeller in its drive to create a new breed of biotech

7 years ago

As with children studies, Supernus ADHD drug shows fast onset of action in adolescents

7 years ago

The year of living large: A fledgling Relay Therapeutics reaps a whopping $400M venture round, with SoftBank pointing ...

7 years ago

Biotech bound, Liz Barrett passes Novartis' top oncology job to Susanne Schaffert

7 years ago

After abruptly pulling its marketing application, DBV may be left with peanuts in race against Aimmune

7 years ago

FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in ...

7 years ago

That’s gotta hurt. FDA turns thumbs down on Spectrum’s 'breakthrough' pitch for cancer drug poziotinib and shares ...

7 years ago

Vivek Ramaswamy bags option rights on Daiichi’s pipeline drugs; Achillion drops a lead program; Ziopharm creates ...

7 years ago

RiverVest ready to roll with Fund IV after closing the till with $184M

7 years ago

John Johnson is back trying his hand as a turnaround artist for a troubled biotech. Can he win this time?

7 years ago

Gilead dangles $105M in quick cash to sign Scholar Rock to a discovery deal for its growing NASH pipeline

7 years ago

Roche, Alexion ripe for showdown in a race to treat rare CNS disorder

7 years ago

Annexon grabs $75M to pay for push into PhII studies for C1q drugs

7 years ago

With cancer in focus, Amgen taps Molecular Partners' preclinical immune-oncology asset for $50M upfront

7 years ago

Aiming to shed last-place rep, Eli Lilly touts its PhIII pipeline and promises a faster game in R&D

7 years ago

Ready to consummate its Shire buyout, Takeda plans US dual listing while NYSE loses a major pharma to Nasdaq

7 years ago

GSK, Pfizer to create consumer health powerhouse under JV — then spin it out

7 years ago

Little Tetra is prepping a PhII Alzheimer’s study. In fact, they just got $40M to fund it

7 years ago

Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug

7 years ago

Reimagining medicine? Novartis wraps pharma’s first big global pot deal

7 years ago

First page Previous page 972 973 974975976 977 978 Next page Last page